We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-5.26%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$437M
AUM Growth
+$14M
Cap. Flow
+$60.4M
Cap. Flow %
13.81%
Top 10 Hldgs %
66.91%
Holding
28
New
6
Increased
6
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$34.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.1M
3
ONC
BeOne Medicines Ltd
ONC
+$17.4M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$11.5M
5
COGT icon
Cogent Biosciences
COGT
+$8.19M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$16.3M
2
INSM icon
Insmed
INSM
+$13M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$13M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.56M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$6.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
$2.73M 0.63%
911,736
– –
ALLK
27
DELISTED
Allakos
ALLK
$461K 0.11%
147,189
– –
PTGX icon
28
Protagonist Therapeutics
PTGX
$8.76B
– –
-549,988
Closed -$13M
1
2

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q2 2022 Portfolio in Review

As of Q2 2022, Fairmount Funds Management held 28 positions worth $437M, up 3.3% from $423M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Fairmount Funds Management deployed $60.4M of net new capital in Q2 2022, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 3,343,107 shares worth $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $16.3M trimmed.

  • Fairmount Funds Management's largest Q2 2022 buy was BioCryst Pharmaceuticals: 3,343,107 shares worth $35.4M.
  • Fairmount Funds Management added most to Cogent Biosciences in Q2 2022, an estimated $8.19M increase.
  • Fairmount Funds Management's biggest Q2 2022 reduction was argenx, cutting an estimated $16.3M.
  • Fairmount Funds Management fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $13M.
  • Fairmount Funds Management's ten largest holdings make up 67% of its $437M portfolio in Q2 2022.
  • Fairmount Funds Management opened 6 new positions and closed 1 in Q2 2022.
  • Fairmount Funds Management's portfolio value rose 3.3% quarter-over-quarter to $437M.

Based on Fairmount Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.